# Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy

> **NCT04149821** · PHASE2 · TERMINATED · sponsor: **Weill Medical College of Cornell University** · enrollment: 1 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia
- CLL Progression
- CLL/SLL

## Interventions

- **DRUG:** Umbralisib
- **DRUG:** Ublituximab

## Key facts

- **NCT ID:** NCT04149821
- **Lead sponsor:** Weill Medical College of Cornell University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-02-10
- **Primary completion:** 2022-01-21
- **Final completion:** 2022-06-09
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Terminated due to low accrual
- **Last updated:** 2023-06-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04149821

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04149821, "Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT04149821. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*